Arcellx, Inc.

Historical 13F Holders

Symbol
ACLX
CUSIP
03940C100
All holders as of
Q2 2026
Type
Equity
Class
COMMON STOCK
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 03940C100 since 12/18/2024, largest first.

Filer % of Class Filed
Gilead Sciences, Inc. 13D/A 100.0% 4/28/2026
Event 4/28/2026
BlackRock, Inc. 13G/A 6.4% 4/17/2025
Event 3/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (9)
T. Rowe Price Investment Management, Inc. 13G/A 4.5% 3/6/2026
Event 2/28/2026
Perceptive Advisors LLC 13G/A
4.5% 8/14/2025
Event 6/30/2025
RA Capital Management, L.P. 13G/A
2.2% 2/17/2026
Event 12/31/2025
FMR LLC 13G/A
0.5% 3/6/2026
Event 2/27/2026
Rami Elghandour 13D/A 0% 4/28/2026
Event 4/28/2026
New Enterprise Associates 15, L.P. 13D/A
0% 4/30/2026
Event 4/28/2026
Paradigm Biocapital Advisors LP 13G/A
0% 8/14/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026
Vestal Point Capital, LP 13G/A
0% 5/15/2026
Event 3/31/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 2 30.0 k $3.43 M
2026 Q1 267 57.0 M $6.52 B
2025 Q4 232 72.3 M $4.71 B
2025 Q3 224 63.9 M $5.25 B
2025 Q2 218 61.4 M $4.01 B
2025 Q1 216 61.9 M $4.06 B
2024 Q4 227 59.2 M $4.54 B
2024 Q3 207 49.7 M $4.15 B
2024 Q2 176 51.9 M $2.86 B
2024 Q1 194 50.3 M $3.50 B
2023 Q4 171 49.6 M $2.75 B
2023 Q3 143 48.7 M $1.75 B
2023 Q2 145 49.3 M $1.56 B
2023 Q1 126 46.7 M $1.44 B
2022 Q4 133 44.2 M $1.37 B
2022 Q3 79 42.9 M $805 M
2022 Q2 69 34.9 M $622 M
2022 Q1 50 26.9 M $358 M